Skip to content

Gut microbiota influence the therapeutic efficacy of HER2-targeted treatment in breast cancer by regulating tumour-infiltrating lymphocytes

Gut microbiota influence the therapeutic efficacy of HER2-targeted treatment in breast cancer by regulating tumour-infiltrating lymphocytes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063560
Enrollment
Unknown
Registered
2022-09-11
Start date
2022-09-26
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

pCR group and non-pCR group:neoadjuvant therapy with TCbHP or THP regimen

Sponsors

Chongqing General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1).20-60 years old. 2).HER-2-positive breast cancer diagnosed by percutaneous core needle puncture biopsy and immunohistochemical staining. 3).Proposed neoadjuvant therapy with TCbHP or THP regimen. 4).Without use of antibiotics 3 months before the first neoadjuvant therapy. 5).Without history of constipation or diarrhea 2 weeks before the first neoadjuvant therapy. 6).Written informed consent should be obtained from all participants.

Exclusion criteria

Exclusion criteria: 1). Suffering from diseases of the intestinal tract. 2). Suffering from infectious diseases (HIV, tuberculosis, syphilis, etc.). 3). Suffering from metabolic diseases such as diabetes mellitus. 4). Patients with liver or kidney insufficiency. 5). Pregnant or lactant patients. 6). Those with poor compliance, as judged by the combination.

Design outcomes

Primary

MeasureTime frame
Gut microbiota of the patients;

Secondary

MeasureTime frame
Paraffin section of tumor specimens;

Countries

CHINA

Contacts

Public ContactSupeng Yin
yinsupeng@163.com18716352727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026